Treatment of age‐related macular degeneration

Bylsma, Guy; Guymer, Robyn H.

doi:10.1111/j.1444-0938.2005.tb06716.x

Cited by 20 publications

(8 citation statements)

References 125 publications

(106 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RP, an inherited disease, afflicts approximately 1 in 3700, or roughly 80,000 people in the United States [3]. Current treatments for wet AMD consist of laser photocoagulation, photodynamic therapy using the photosensitizing dye verteporfin (Visudyne ® , Novartis), and anti-angiogenesis therapy using the oligonucleotide antagonist pegaptanib (Macugen ® , Eyetech Pharmaceuticals and Pfizer) [4], the VEGF antibody fragment ranibizumab (Lucentis ™ , Genentech), and the VEGF antibody bevacizumab (Avastin ™ , Genentech). Preventative measures such as anti-oxidant supplements [5] and smoking cessation [6] also show some effectiveness.…”

Section: Introductionmentioning

confidence: 99%

A microfabricated scaffold for retinal progenitor cell grafting

et al. 2008

View full text Add to dashboard Cite

Diseases that cause photoreceptor cell degeneration afflict millions of people, yet no restorative treatment exists for these blinding disorders. Replacement of photoreceptors using retinal progenitor cells (RPCs) represents a promising therapy for the treatment of retinal degeneration. Previous studies have demonstrated the ability of polymer scaffolds to increase significantly both the survival and differentiation of RPCs. We report the microfabrication of a poly(glycerol-sebacate) scaffold with superior mechanical properties for the delivery of RPCs to the subretinal space. Using a replica molding technique, a porous poly(glycerol-sebacate) scaffold with a thickness of 45 microm was fabricated. Evaluation of the mechanical properties of this scaffold showed that the Young's modulus is about 5-fold lower and the maximum elongation at failure is about 10-fold higher than the previously reported RPC scaffolds. RPCs strongly adhered to the poly(glycerol-sebacate) scaffold, and endogenous fluorescence nearly doubled over a 2-day period before leveling off after 3 days. Immunohistochemistry revealed that cells grown on the scaffold for 7 days expressed a mixture of immature and mature markers, suggesting a tendency towards differentiation. We conclude that microfabricated poly(glycerol-sebacate) exhibits a number of novel properties for use as a scaffold for RPC delivery.

show abstract

Section: Introductionmentioning

confidence: 99%

A microfabricated scaffold for retinal progenitor cell grafting

et al. 2008

View full text Add to dashboard Cite

show abstract

“…AMD is a chronic and progressive retinal degenerative disease. At early stages, AMD is characterized by generation of drusen in the macular area and hyper- or hypo-pigmentation of the RPE (Bylsma, 2005; Provis et al, 2005). At late stages, AMD appears in two major forms, the dry AMD and wet AMD.…”

Section: Introductionmentioning

confidence: 99%

Photoreceptor degeneration and retinal inflammation induced by very low-density lipoprotein receptor deficiency

Chen

Moiseyev

et al. 2009

Microvascular Research

View full text Add to dashboard Cite

Our previous studies have shown that very low-density lipoprotein receptor (VLDLR) is a negative regulator of the Wnt pathway. The present study showed that VLDLR gene knockout (Vldlr −/− ) mice displayed impaired cone ERG responses at early ages. Immunostaining of mid-wavelength cones showed significantly decreased cone densities in the retina and shortened cone outer segments in Vldlr −/− mice. At older ages, Vldlr −/− mice displayed declined rod ERG responses, decreased layers of photoreceptor nuclei, reduced rhodopsin levels and decreased levels of 11-cis retinal, the chromophore of visual pigments. As shown by fluorescein angiography and permeability assay, Vldlr −/− mice had severe retinal vascular leakage. ZO-1, a tight junction protein, was down-regulated in Vldlr −/− mouse retinae, further supporting the impaired blood-retinal barrier. Double staining of pericytes and endothelial cells in retinal sections revealed that neovasculature in Vldlr −/− mice lacks pericyte coverage, suggesting impaired maturation of retinal vasculature in Vldlr −/− mice. Staining of adherent leukocytes in the retinal vasculature revealed significant leukostasis in Vldlr −/− mice. Moreover, Vldlr −/− mice displayed up-regulated expression of multiple pro-inflammatory factors and activated NF-κB and HIF-1α, key regulators of inflammation. These findings suggest that deficiency of VLDLR leads to retinal degeneration and inflammation.

show abstract

“…2 There are few known risk factors and evidence for the prevention of AMD remains intangible. 3 While intensive research continues into new treatments, potential new environmental and genetic risk factors, and predictive and preventative measures, 2 3 there has been less focus on the impact of vision impairment on people with AMD. Clinicians and the community in general undervalue or are not well aware of the broad impact of AMD on health related quality of life.…”

mentioning

confidence: 99%

Impact of age related macular degeneration on quality of life

Hassell

Lamoureux²,

Keeffe³

2006

British Journal of Ophthalmology

207

148

View full text Add to dashboard Cite

Aims: To describe the impact of age related macular degeneration (AMD) on quality of life and explore the association with vision, health, and demographic variables. Methods: Adult participants diagnosed with AMD and with impaired vision (visual acuity ,6/12) were assessed with the Impact of Vision Impairment (IVI) questionnaire. Participants rated the extent that vision restricted participation in activities affecting quality of life and completed the Short Form General Health Survey (SF-12) and a sociodemographic questionnaire. Results: The mean age of the 106 participants (66% female) was 83.6 years (range 64-98). One quarter had mild vision impairment, (VA,6/12-6/18) and 75% had moderate or severely impaired vision. Participants reported from at least ''a little'' concern on 23 of the 32 IVI items including reading, emotional health, mobility, and participation in relevant activities. Those with mild and moderate vision impairment were similarly affected but significantly different from those with severe vision loss (p,0.05). Distance vision was associated with IVI scores but not age, sex, or duration of vision loss. Conclusion: AMD affects many quality of life related activities and not just those related to reading. Referral to low vision care services should be considered for people with mild vision loss and worse.A ge related macular degeneration (AMD) is a leading cause of vision impairment in the developed world.1 Success of treatment is often defined in terms of preservation of remaining vision rather than improvement in vision.2 There are few known risk factors and evidence for the prevention of AMD remains intangible.3 While intensive research continues into new treatments, potential new environmental and genetic risk factors, and predictive and preventative measures, 2 3 there has been less focus on the impact of vision impairment on people with AMD. Clinicians and the community in general undervalue or are not well aware of the broad impact of AMD on health related quality of life. 4 We know vision loss is associated with increased morbidity, including an increased risk of falls. 5 6 Recent research has shown how vision impairment compromises quality of life and limits social interaction and independence.6 7 Vision impairment caused by AMD has also been shown to interfere with the person's ability to care for themselves and others indicating need for community and vision related support. 8Vision loss from AMD has been shown to be associated with depression and that significant psychological distress is similar to that of people with other serious chronic illness. 9 10 Therefore, the current lack of effective preventive measures and treatment for most people with AMD emphasises the importance of timely referral and vision rehabilitation, yet only a small proportion of people with impaired vision access low vision rehabilitation services. [11][12][13] Consequently, the aim of this paper was to describe the impact of vision loss from AMD on a broad range of daily life activities and to determine the ...

show abstract

Treatment of age‐related macular degeneration

Cited by 20 publications

References 125 publications

A microfabricated scaffold for retinal progenitor cell grafting

A microfabricated scaffold for retinal progenitor cell grafting

Photoreceptor degeneration and retinal inflammation induced by very low-density lipoprotein receptor deficiency

Impact of age related macular degeneration on quality of life

Contact Info

Product

Resources

About